The company’s chief executive said on Sunday that the COVID-19 vaccine jointly developed by the British AstraZeneca Pharmaceutical Group and the University of Oxford has achieved a “successful formula.”
In an interview with The Sunday Times, Pascal Soriot said that the vaccine is currently being evaluated by the UK’s independent drug regulatory agency and can provide “100% protection” for severe COVID disease that requires hospitalization.
He added that he believes the trial will prove that his company has achieved vaccine efficacy equal to 95% of Pfizer-BioNTech and 94.5% of Moderna.
Get the daily edition of The Times of Israel via email. Don’t miss our hot news. Sign up for free
The CEO said: “We think we have figured out the winning formula and how to achieve the same efficacy as everyone else after two doses,”
The British government announced on December 23 that the developer of the Oxford-AstraZeneca vaccine had submitted its data to the Medicines and Medical Products Regulatory Agency (MHRA).
According to the “Sunday Telegraph” report, the filming is expected to be approved on Monday.
The Pfizer-BioNTech vaccine is the first coronavirus vaccine approved for use by the UK’s independent drug regulatory agency and has been vaccinated to the country’s 600,000 most vulnerable people since last month.
Earlier trials have shown that the efficacy of AstraZeneca lenses has different results. The vaccine initially showed an average 70% effectiveness, but depending on the dose, the level jumped to 90%.
“Storm” of data
Behind this average figure in large-scale trials conducted in the United Kingdom and Brazil, those who received two full doses of the vaccine had an effectiveness of 62%.
However, for volunteers who received a half dose and then a full dose one month later, the vaccine was found to be 90% effective.
Soriot said he was “surprised” by the initial findings. He added: “We want a simpler set of results.”
People are generally criticized for the lack of clarity and transparency of the difference in results. Soriot said he did not expect to follow.
He said: “It is certain that people will be a little disappointed.” “But we did not expect such a storm.”
Because of its low cost, the original AstraZeneca lens based on the weakened chimpanzee virus has given great hope.
AstraZeneca’s vaccine also has logistical advantages over Pfizer-BioNTech alternatives because it can be stored, transported and processed for at least six months under normal cold storage conditions of 2 to 8 degrees Celsius (36-46 degrees Fahrenheit).
This is far from the -70C required for Pfizer/BioNTech products and can allow the use of existing cold storage supply chains to reduce costs.
‘Light at the end of the tunnel’
In a vote of confidence in its domestic vaccine, it is expected that the injection of the vaccine will meet most of the requirements of the UK.
The government has ordered 100 million doses and plans to provide 40 million doses by the end of March.
British officials hope that this trust will be rewarded, not only because the country is one of the countries most affected by the pandemic, with more than 70,000 deaths.
In the past week, there has been a surge in cases nationwide, especially in the south-east of England, and has been attributed to a new virus believed to be more contagious, which was first detected in the UK.
According to a British study, this strain is 50% to 74% more infectious.
In order to curb the spread of the disease, stricter lockdown restrictions that took effect on December 26 have restricted millions of people across the UK.
Dozens of countries have also imposed travel restrictions on the UK to prevent the spread of new strains.
Finance Minister Rishi Sunak wrote in the Sunday newspaper’s “Mail” that “it has been a difficult year for everyone in this country”.
However, he added: “The early launch of the vaccine-the incredible work done by our scientists and the NHS-means we can now see the light at the end of the tunnel.”
The British drug manufacturer said it will produce nearly 200 million doses of AstraZeneca vaccine by the end of this year, and more than 700 million doses will be produced globally by the end of March next year.